News

MCC's Leadership program is a collaboration of member companies that define industry benchmark measures for Life Science organizations engaged in starting clinical trials.

Clintrax Global provides outsourced services for negotiating clinical trial-related contracts and budgets between biopharmaceutical, CROs and investigator sites.

Ambry Genetics' CEO discusses his company's decision to release the genetic information of its customers for free - a rare move, reportedly, for a commercial testing firm.

Exco InTouch has integrated its ePRO solution with Oracle Health Sciences’ InForm EDC system to provide a data capture solution for both clinical and post-marketing studies.

The CLIA-accredited laboratory will support both research-use-only and clinical diagnostic tests.

‘PRIME’ (short for 'PRIority Medicines') will offer early advice to medicine developers so that they have the best chance of producing robust data on benefits and risks, and allow more rapid assessment.

The software allows pathology labs, hospitals, genomic cores and physicians to match patients’ test results to personalized cancer treatments, including clinical trials and experimental drugs.

Sponsors now take different approaches for “regulatory” trials to gain market registration, and “real world” studies to determine how a product should be used in practice, but these two worlds should not be separate.

Use the “CLEAR” path to effectively engage patients and build their confidence in an increasingly digital and mobile pharmaceutical environment.

The eClinical division of Merge Healthcare, an IBM company, will continue to participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.

A recent survey by Worldwide Clinical Trials showed coordinators' are concerned eCOA interferes with normal patient rapport.

ACS and Quintiles will build a comprehensive and integrated clinical registry platform that combines data from more than 1,800 hospitals across the United States, international medical contributors and individual surgeons to improve surgical patient care outcomes.

Nonclinical models are limited, and clinical trials are challenging because, among many factors, is that pain is subjective, making it hard to define objective endpoints or to compare one drug to another.

The collaboration will allow joint customers to securely combine data from all site-facing applications using single sign-on with non-site facing data sources.

The contract negotiation process is generally believed to be the primary bottleneck in site startup and MAGI's CTA template would help that process.

The addition of Research Across America's sites means that Synexus can now offer extra capacity, particular U.S. market expertise and therapeutic experience.

R&G provides a full range of clinical trial services for both domestic and global partners.